Talabot-Ayer D - Search Results

1

IL-36R ligands are potent regulators of dendritic and T cells.

Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E, Ronchi F, Sallusto F, Dinh H, Sims JE, Gabay C. Vigne S, et al. Blood. 2011 Nov 24;118(22):5813-23. doi: 10.1182/blood-2011-05-356873. Epub 2011 Aug 22. Blood. 2011. PMID: 21860022 Free article.

2

The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters.

Talabot-Ayer D, Calo N, Vigne S, Lamacchia C, Gabay C, Palmer G. Talabot-Ayer D, et al. J Leukoc Biol. 2012 Jan;91(1):119-25. doi: 10.1189/jlb.0811425. Epub 2011 Oct 19. J Leukoc Biol. 2012. PMID: 22013230

3

Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions.

Martin P, Palmer G, Vigne S, Lamacchia C, Rodriguez E, Talabot-Ayer D, Rose-John S, Chalaris A, Gabay C. Martin P, et al. Among authors: talabot ayer d. J Leukoc Biol. 2013 Oct;94(4):791-802. doi: 10.1189/jlb.0113035. Epub 2013 Jul 1. J Leukoc Biol. 2013. PMID: 23817563

4

Immune-mediated experimental arthritis in IL-33 deficient mice.

Talabot-Ayer D, Martin P, Seemayer CA, Vigne S, Lamacchia C, Finckh A, Saiji E, Gabay C, Palmer G. Talabot-Ayer D, et al. Cytokine. 2014 Sep;69(1):68-74. doi: 10.1016/j.cyto.2014.05.007. Epub 2014 Jun 11. Cytokine. 2014. PMID: 25022964

5

Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation.

Palmer G, Talabot-Ayer D, Kaya G, Gabay C. Palmer G, et al. J Invest Dermatol. 2007 Aug;127(8):1938-46. doi: 10.1038/sj.jid.5700803. Epub 2007 May 3. J Invest Dermatol. 2007. PMID: 17476299 Free article.

6

Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells.

Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Moulin D, et al. Cytokine. 2007 Dec;40(3):216-25. doi: 10.1016/j.cyto.2007.09.013. Epub 2007 Nov 19. Cytokine. 2007. PMID: 18023358

7

The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33.

Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, Gabay C, Smith DE. Palmer G, et al. Cytokine. 2008 Jun;42(3):358-64. doi: 10.1016/j.cyto.2008.03.008. Epub 2008 May 2. Cytokine. 2008. PMID: 18450470

8

Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C. Palmer G, et al. Arthritis Rheum. 2009 Mar;60(3):738-49. doi: 10.1002/art.24305. Arthritis Rheum. 2009. PMID: 19248109 Free article.

9

Interleukin-33 is biologically active independently of caspase-1 cleavage.

Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Talabot-Ayer D, et al. J Biol Chem. 2009 Jul 17;284(29):19420-6. doi: 10.1074/jbc.M901744200. Epub 2009 May 22. J Biol Chem. 2009. PMID: 19465481 Free PMC article.

10

Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist.

Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C. Lamacchia C, et al. Arthritis Rheum. 2010 Feb;62(2):452-62. doi: 10.1002/art.27235. Arthritis Rheum. 2010. PMID: 20112392 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page